Characterising cause of death among people treated for drug-susceptible TB in India

CTRIUMPH and TBDM Study Teams

doi:10.5588/ijtld.22.0454

Characterising cause of death among people treated for drug-susceptible TB in India

CTRIUMPH and TBDM Study Teams

School of Medicine

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	78-80
Number of pages	3
Journal	International Journal of Tuberculosis and Lung Disease
Volume	27
Issue number	1
DOIs	https://doi.org/10.5588/ijtld.22.0454
State	Published - Jan 1 2023

ASJC Scopus subject areas

General Medicine

Access to Document

10.5588/ijtld.22.0454

Cite this

@article{e258d74c1f904fcd90c9e9812bc71967,

title = "Characterising cause of death among people treated for drug-susceptible TB in India",

author = "{CTRIUMPH and TBDM Study Teams} and Cox, {S. R.} and C. Padmapriyadarsini and Vidya Mave and B. Seth and K. Thiruvengadam and S. Gaikwad and Sahasrabudhe, {T. R.} and M. Sane and Tornheim, {J. A.} and Shrinivasa, {B. M.} and R. Lokhande and Barthwal, {M. S.} and Shivakumar, {S. V.B.Y.} and S. Krishnan and R. Santhappan and A. Kinikar and Kakrani, {A. L.} and M. Paradkar and Bollinger, {R. C.} and K. Sekar and Gupte, {A. N.} and Hanna, {L. E.} and A. Gupta and Golub, {J. E.}",

note = "Funding Information: The authors would like to thank the study participants and their families for their time and commitment; and the entire Cohort for TB Research by the Indo-US Medical Partnership (CTRIUMPH) and the Impact of Diabetes on TB Treatment Outcomes (TBDM) study teams at Byramjee Jeejeebhoy Government Medical College (Pune), Dr DY Patil Medical College (Pune, Indian Council of Medical Research-National Institute for Research in Tuberculosis (Chennai, India), and Johns Hopkins University (Baltimore, MD, USA). This work was supported by the National Institute of Allergy and Infectious Diseases (NIAID) of the United States National Institutes of Health (NIH; Bethesda, MD, USA) [grant numbers #DAA3-18-64774-1 (CRDF Global), R01AI097494]; the Government of India{\textquoteright}s Department of Biotechnology for the CTRIUMPH Study as part of the Regional Prospective Observational Research for Tuberculosis (RePORT) India Consortium; and Persistent Systems (Pune, India) in kind. In addition, BS was supported by the National Health, Lung and Blood Institute of NIH [grant number # T32HL007534]; JAT received support from NIAID/NIH [grant number K23AI135102] and the RePORT International Coordinating Center; and SK was supported by NIH [grant number T32 AI007291-2]. The contents of this publication are solely the responsibility of the authors and do not represent the official views of the funders. Conflicts of interest: none declared. Funding Information: The authors would like to thank the study participants and their families for their time and commitment; and the entire Cohort for TB Research by the Indo-US Medical Partnership (CTRIUMPH) and the Impact of Diabetes on TB Treatment Outcomes (TBDM) study teams at Byramjee Jeejeebhoy Government Medical College (Pune), Dr DY Patil Medical College (Pune, Indian Council of Medical Research-National Institute for Research in Tuberculosis (Chennai, India), and Johns Hopkins University (Baltimore, MD, USA). This work was supported by the National Institute of Allergy and Infectious Diseases (NIAID) of the United States National Institutes of Health (NIH; Bethesda, MD, USA) [grant numbers #DAA3-18-64774-1 (CRDF Global), R01AI097494]; the Government of India{\textquoteright}s Department of Biotechnology for the CTRIUMPH Study as part of the Regional Prospective Observational Research for Tuberculosis (RePORT) India Consortium; and Persistent Systems (Pune, India) in kind. In addition, BS was supported by the National Health, Lung and Blood Institute of NIH [grant number # T32HL007534]; JAT received support from NIAID/NIH [grant number K23AI135102] and the RePORT International Coordinating Center; and SK was supported by NIH [grant number T32 AI007291-2]. The contents of this publication are solely the responsibility of the authors and do not represent the official views of the funders.",

year = "2023",

month = jan,

day = "1",

doi = "10.5588/ijtld.22.0454",

language = "English (US)",

volume = "27",

pages = "78--80",

journal = "International Journal of Tuberculosis and Lung Disease",

issn = "1027-3719",

publisher = "International Union against Tubercul. and Lung Dis.",

number = "1",

}

TY - JOUR

T1 - Characterising cause of death among people treated for drug-susceptible TB in India

AU - CTRIUMPH and TBDM Study Teams

AU - Cox, S. R.

AU - Padmapriyadarsini, C.

AU - Mave, Vidya

AU - Seth, B.

AU - Thiruvengadam, K.

AU - Gaikwad, S.

AU - Sahasrabudhe, T. R.

AU - Sane, M.

AU - Tornheim, J. A.

AU - Shrinivasa, B. M.

AU - Lokhande, R.

AU - Barthwal, M. S.

AU - Shivakumar, S. V.B.Y.

AU - Krishnan, S.

AU - Santhappan, R.

AU - Kinikar, A.

AU - Kakrani, A. L.

AU - Paradkar, M.

AU - Bollinger, R. C.

AU - Sekar, K.

AU - Gupte, A. N.

AU - Hanna, L. E.

AU - Gupta, A.

AU - Golub, J. E.

N1 - Funding Information: The authors would like to thank the study participants and their families for their time and commitment; and the entire Cohort for TB Research by the Indo-US Medical Partnership (CTRIUMPH) and the Impact of Diabetes on TB Treatment Outcomes (TBDM) study teams at Byramjee Jeejeebhoy Government Medical College (Pune), Dr DY Patil Medical College (Pune, Indian Council of Medical Research-National Institute for Research in Tuberculosis (Chennai, India), and Johns Hopkins University (Baltimore, MD, USA). This work was supported by the National Institute of Allergy and Infectious Diseases (NIAID) of the United States National Institutes of Health (NIH; Bethesda, MD, USA) [grant numbers #DAA3-18-64774-1 (CRDF Global), R01AI097494]; the Government of India’s Department of Biotechnology for the CTRIUMPH Study as part of the Regional Prospective Observational Research for Tuberculosis (RePORT) India Consortium; and Persistent Systems (Pune, India) in kind. In addition, BS was supported by the National Health, Lung and Blood Institute of NIH [grant number # T32HL007534]; JAT received support from NIAID/NIH [grant number K23AI135102] and the RePORT International Coordinating Center; and SK was supported by NIH [grant number T32 AI007291-2]. The contents of this publication are solely the responsibility of the authors and do not represent the official views of the funders. Conflicts of interest: none declared. Funding Information: The authors would like to thank the study participants and their families for their time and commitment; and the entire Cohort for TB Research by the Indo-US Medical Partnership (CTRIUMPH) and the Impact of Diabetes on TB Treatment Outcomes (TBDM) study teams at Byramjee Jeejeebhoy Government Medical College (Pune), Dr DY Patil Medical College (Pune, Indian Council of Medical Research-National Institute for Research in Tuberculosis (Chennai, India), and Johns Hopkins University (Baltimore, MD, USA). This work was supported by the National Institute of Allergy and Infectious Diseases (NIAID) of the United States National Institutes of Health (NIH; Bethesda, MD, USA) [grant numbers #DAA3-18-64774-1 (CRDF Global), R01AI097494]; the Government of India’s Department of Biotechnology for the CTRIUMPH Study as part of the Regional Prospective Observational Research for Tuberculosis (RePORT) India Consortium; and Persistent Systems (Pune, India) in kind. In addition, BS was supported by the National Health, Lung and Blood Institute of NIH [grant number # T32HL007534]; JAT received support from NIAID/NIH [grant number K23AI135102] and the RePORT International Coordinating Center; and SK was supported by NIH [grant number T32 AI007291-2]. The contents of this publication are solely the responsibility of the authors and do not represent the official views of the funders.

PY - 2023/1/1

Y1 - 2023/1/1

UR - http://www.scopus.com/inward/record.url?scp=85149154639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85149154639&partnerID=8YFLogxK

U2 - 10.5588/ijtld.22.0454

DO - 10.5588/ijtld.22.0454

M3 - Letter

C2 - 36853129

AN - SCOPUS:85149154639

SN - 1027-3719

VL - 27

SP - 78

EP - 80

JO - International Journal of Tuberculosis and Lung Disease

JF - International Journal of Tuberculosis and Lung Disease

IS - 1

ER -

Characterising cause of death among people treated for drug-susceptible TB in India

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this